科笛完成CU-20401II期临床试验
财中社12月31日电科笛-B（02487）发布公告称，公司已完成CU-20401（重组突变胶原酶）在中国进行的II期临床试验，旨在治疗颏下脂肪堆积。试验结果显示，高剂量组和低剂量组的治疗有效率均显著高于安慰剂组，并且有效率差异具有统计学意义。试验共入组108例受试者，按照1:1:1的比例随机分配至三个组别，受试者用药依从性为100%。
在安全性方面，高剂量组和低剂量组在整个试验期间均未发生严重不良事件，整体安全性可控。CU-20401通过降解皮下脂肪层中的细胞外基质胶原蛋白，预计可有效减少局部脂肪堆积。公司提醒股东和潜在投资者，无法确保最终成功开发及销售CU-20401，建议在买卖股份时保持谨慎。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10